Skip to main content

Trials and the importance of usual care

Dear Editor,

We read with great interest the REDUSE trial paper by Linden and colleagues [1] and particularly commend the comprehensive protocol that recognised the importance of nutrition to fluid accumulation [2] and detailed instructions on concentrating drug administration.

However, we are concerned about the external validity of fluid input with the usual care arm of the REDUSE trial. Such patients received a median fluid input of 9.76 L in the first three days of ICU stay.

In 6412 patients with septic shock, from a previously described cohort [3], admitted to 12 participating ICUs in Australia we found a median fluid input over the first 3 days, D0–D3, of 5.99 L. The overall fluid input over the first three days of ICU admission, together with the single-day breakdown is presented in Fig. 1. The median fluid input of under 6 L was the same as the 6.01 L reported in the intervention arm of the REDUSE trial, demonstrating different baseline practices.

Fig. 1
figure 1

Fluid Administration in patients admitted to ICU with septic shock all sources of fluid input included (crystalloids, colloids, blood products nutrition, and oral sources

Furthermore, recent evidence in renal replacement therapy has demonstrated profound geographical variation in fluid management practices [4]. The assumption that the results of the trial can applied to different jurisdictions may be inaccurate and could have consequences on future, multinational interventional trials, and, ultimately, patient care.

Second, we would like to stress that the REDUSE trial intervention did not highlight the impact on fluid balance, as this information is relegated to the supplemental material. Recent work in critically ill patients with acute kidney injury has demonstrated the importance of urine output and diuretic therapy to the multi-factor development of fluid accumulation [2]. In the REDUSE trial cumulative fluid balance at day 3 was + 2317 mL in the usual care arm, whereas, in our cohort of > 6000 patients, the median cumulative FB was + 544 mL, D0–D3.

We believe that addressing these concerns will contribute to a more comprehensive understanding of fluid management in critically ill patients and guide future research in this important area.

References

  1. Lindén A, Spångfors M, Olsen MH, Fisher J, Lilja G, Sjövall F, et al. Protocolized reduction of non-resuscitation fluids versus usual care in septic shock patients (REDUSE): a randomized multicentre feasibility trial. Crit care (Lond, Engl). 2024;28(1):166.

    Article  Google Scholar 

  2. White KC, Serpa-Neto A, Hurford R, Clement P, Laupland KB, Ostermann M, et al. How a positive fluid balance develops in acute kidney injury: A binational, observational study. J Crit Care. 2024;82:154809.

    Article  PubMed  Google Scholar 

  3. White KC, Serpa-Neto A, Hurford R, Clement P, Laupland KB, See E, et al. Sepsis-associated acute kidney injury in the intensive care unit: incidence, patient characteristics, timing, trajectory, treatment, and associated outcomes. A multicenter, observational study. Intensiv Care Med. 2023;49:1–11.

    Article  Google Scholar 

  4. Vaara ST, Neto AS, Bellomo R, Adhikari NKJ, Dreyfuss D, Gallagher M, et al. Regional practice variation and outcomes in the standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI) trial: a post hoc secondary analysis. Crit Care Explor. 2024;6(2):e1053.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

Authors

Consortia

Contributions

All authors (KW, KL, and RB) were involved in the concept, drafting, and review of final version.

Corresponding author

Correspondence to Kyle C. White.

Ethics declarations

Ethics approval and consent to participate

The data presented in this correspondence was approved by the Metro South Hospital and Health Service Human Research Ethics Committee (HREC/2022/QMS/82024) with an individual waiver of consent granted.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

White, K.C., Laupland, K.B., Bellomo, R. et al. Trials and the importance of usual care. Crit Care 28, 223 (2024). https://doi.org/10.1186/s13054-024-04977-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13054-024-04977-1